National Clinical Evidence Taskforce (Australia), 2022 The National Clinical Evidence Taskforce aims to support Australia’s healthcare professionals caring for people with urgent and emerging diseases, by providing continually updated, evidence-based clinical guidelines. The Taskforce, an alliance between 35 member organisations, established the world’s first ‘living guidelines’...
Hepatitis Australia, 3 April 2020 Hepatitis Australia warmly welcomes recent changes to the Pharmaceutical Benefits Scheme (PBS) allowing authorised Nurse Practitioners to prescribe hepatitis B and hepatitis C medicines under the Highly Specialised Drugs (s100) Program. Both hepatitis B and hepatitis C are under-treated and without improvement in a range of areas Australia risks falling short of...
Australian Federation of AIDS Organisations (AFAO), March 30th 2020 From 1 April 2020 Truvada for HIV treatment and for pre-exposure prophylaxis (PrEP) will no longer be available through the Pharmaceutical Benefits Scheme (PBS). There are alternatives to Truvada for PrEP in Australia. Community members eligible for PrEP can access generic versions of Truvada supplied by Apotex, Mylan and Lupin...
Identifying and Plugging the Leaks: Gaps And Policy Barriers To Engagement With The HIV Cascade Of Care CTAC (Canadian Treatment Action Council), 2018 This project explored what issues impact engagement by people living with HIV with healthcare in Ontario. The goal was to identify policy issues that impact treatment access for people living with HIV, and to identify opportunities to make the...
ABC Health & Wellbeing, 20/10/2017 25 percent of Australians who menstruate experience heavy menstrual bleeding. Now, new guidelines for doctors will help ensure these people have access to the best available treatment for heavy menstrual bleeding. Professor Anne Duggan, senior medical advisor at the Australian Commission on Safety and Quality in Health Care, said some patients were not being...